Flag of the European Union EU Clinical Trials Register Help

Clinical trials for computed tomography

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    948 result(s) found for: computed tomography. Displaying page 6 of 48.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2016-004928-39 Sponsor Protocol Number: D-FR-01070-002 Start Date*: 2017-11-23
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumo...
    Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024044-15 Sponsor Protocol Number: BMS747158-301 Start Date*: 2011-06-08
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006053-25 Sponsor Protocol Number: IOM/BRA/034 Start Date*: 2006-08-02
    Sponsor Name:Bracco ALTANA Pharma GmbH
    Full Title: PET/CT WITH IOMERON® 400 IN PATIENTS WITH SUSPECTED MALIGNANT LIVER LESIONS - A FEASIBILITY STUDY
    Medical condition: Indication for POSITRON EMISSION TOMOGRAPHY (PET MeDRA 9.0 LLT 10036223) and Computed tomography (Computerized tomography (CT MeDRA 9.0 LLT 10062404) in patients with highly suspected or proved m...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025623 Malignant liver tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019214-25 Sponsor Protocol Number: AXP-CT-001 Start Date*: 2010-08-24
    Sponsor Name:Axcentua Pharmaceuticals AB
    Full Title: Safety, pharmacokinetics and efficacy of AXP107-11 in combination with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the ...
    Medical condition: Histologically confirmed, unresectable, locally advanced or metastatic pancreatic cancer stage III-IV
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    16.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002678-29 Sponsor Protocol Number: BMS747158-302 Start Date*: 2013-02-21
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000381-11 Sponsor Protocol Number: CCMK389X2201 Start Date*: 2020-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar...
    Medical condition: Chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000675-16 Sponsor Protocol Number: CBEZ235F2201 Start Date*: 2012-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuro...
    Medical condition: Adult patient in advanced pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) NL (Completed) DE (Completed) IT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004521-32 Sponsor Protocol Number: D5780C00007 Start Date*: 2018-08-22
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003391-13 Sponsor Protocol Number: D3250C00059 Start Date*: 2019-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asth...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-004386-15 Sponsor Protocol Number: MBG308 Start Date*: Information not available in EudraCT
    Sponsor Name:GE Healthcare Limited and its affiliates
    Full Title: An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma
    Medical condition: Phaeochromocytoma and Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004232-37 Sponsor Protocol Number: D5134C00003 Start Date*: 2017-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Strok...
    Medical condition: Ischaemic stroke, transient ischaemic attack
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) BG (Completed) FR (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) SK (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-004601-47 Sponsor Protocol Number: CKJX839D12303 Start Date*: 2022-05-09
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled, parallelgroup Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed ...
    Medical condition: Non-obstructive coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003265-19 Sponsor Protocol Number: PD0053 Start Date*: 2021-06-07
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkins...
    Medical condition: Early-stage Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PL (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019765-28 Sponsor Protocol Number: SP0993 Start Date*: 2011-02-08
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200M...
    Medical condition: Epilepsy, partial onset or generalised tonic-clonic seizures.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) SK (Completed) GB (Completed) GR (Completed) IT (Completed) LV (Completed) LT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003277-15 Sponsor Protocol Number: 8400-211 Start Date*: 2016-09-02
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003978-13 Sponsor Protocol Number: M16-852 Start Date*: 2019-09-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis: Select-GCA
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Completed) DE (Trial now transitioned) PT (Trial now transitioned) GR (Completed) HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002106-13 Sponsor Protocol Number: ATH3G10-005 Start Date*: 2017-09-06
    Sponsor Name:Athera Biotechnologies AB
    Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ...
    Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004374-15 Sponsor Protocol Number: PUMA-NER-6201 Start Date*: 2018-04-13
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
    Medical condition: Early Stage HER2+ Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 18:50:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA